Research Article

The Potential of a Commercial Product based on Bacillus thuringiensis Cry1A-Cry2A Toxins as an Immunogen and Adjuvant

Guerrero GG1*, Favela-Hernández JM2 and Balderas-Rentería I3

1Universidad Autónoma de Zacatecas, Unidad Académica de Ciencias Biológicas, Lab de Immunobiología, Campus II-UAZ, Zacatecas, Zac, México
2Instituto Multidisciplinario de Ciencias (AVICENA), Campus Torreón, Coahuila, México
3Universidad Autónoma de Nuevo León, Departamento de Investigación y Posgrado de la, Facultad de Ciencias Químicas, Lab de Ingeniería Genética y Genómica, Monterrey, Nvo León, México

Abstract

Bacillus thuringiensis Cry toxins are strong immunogen adjuvants and potential carriers of clinically important antigens. However, there are still safety and biological concerns for clinical use. In the present work, strong immunogenicity were measured through antibody production (IgM, IgA, IgG subclasses) (in serum and broncheo-alveolar washes) and pro-inflammatory/anti-inflammatory cytokine induction after intranasal/oral immunization. First, we found that Th1-Th2 cytokines were induced (TNF-α, IFN-γ, IL-6, IL-4) as well as IL-17 and IL-10. Second, a remarkable higher systemic IFN-γ and TNF-α induction after oral immunization. These data were strengthened because no toxic effect in mammalian cells (pneumocytes class II-A549 human cell line) at 10 µg/ml was observed. Conversely; Cry1A toxins acted as an adjuvant of BCG vaccine immunity after A549 co-stimulation with BCG, a boost in the Th1-type response (IFN-γ and IL-12) was induced. In summary, all the data reported here, show that a commercial product based on B. thuringiensis Cry1A-Cry2A toxins is an strong immunogen and adjuvant, both properties could account for the development of non toxic therapeutic agents.

Keywords: Bacillus thuringiensis, Cry1A toxins, Cry2A IL-17, IFN-γ, IgG subclasses.

Introduction

Bacillus thuringiensis (Bt) Cry toxins belongs to a multigenic family of crystalline proteins, or “Cry” [1-3]. In a previous work, we have been shown that Bt tCry1A (1Aa, 1Ab, 1Ac) induce strong immune responses after intraperitoneal or mucosal administration (nasal) [4-8]. However, most of the studies have centered in the protoxin Cry1Ac (pCry1Ac), a strong immunogen, adjuvant and carrier [7-12]. The mechanism of these abilities remains to be defined. At this point, some studies have addressed this issue. For example, it has been demonstrated that there is an initial interaction of pCry1Ac with molecules like receptor [13]; whereas in monocytes elicited a higher expression of FcRn receptor after immunized with pCry1Ac [14] or with mice immune cells [15-16].

From the literature, it is well known that one of the most potent immunogen and adjuvant described until now is the one produced by Vibrio cholerae [17-21]. These properties are highlighted because after intranasal immunization of mice with small doses of cholera toxin, it was sufficient to induce Th17- cellular immune responses after intraperitoneal or mucosal administration (nasal) [4-8]. However, most of the studies have centered in the protoxin Cry1Ac (pCry1Ac), a strong immunogen, adjuvant and carrier [7-12]. The mechanism of these abilities remains to be defined. At this point, some studies have addressed this issue. For example, it has been demonstrated that there is an initial interaction of pCry1Ac with molecules like receptor [13]; whereas in monocytes elicited a higher expression of FcRn receptor after immunized with pCry1Ac [14] or with mice immune cells [15-16].
The safety and biological effects of Cry toxins in mammals have been revisited recently [22]. In addition, several other reports have shown that under specific experimental settings, Bt Cry toxins could exert a toxic effect or deleterious [23-27].

Thus, for example it has been shown that mice fed with transgenic maize and or purified Cry1Ab toxin, elicited humoral and cellular immune responses in serum of mice after sensitization by intraperitoneal or intragastric route. Not induction of IgE or toxicity was seen [26-29]. Moreover, a very recent report suggest that Bt Cry toxins could be used for human purposes but only if they are administered by mucosal, and not by systemic or parenteral route [30]. The data reported here, highlight and strengthened these studies [30] that indicate that B. thuringiensis Cry toxins are safe only after mucosal immunization. In the present work, we found that after either in vivo (BALB/c mice) or in vitro (pneumocytes class II) (A549 human cell line), the commercial product based on Cry1A-Cry2A toxins showed a dichotomy action; either as a strong immunogen through mucosal immunization, of mice and as an adjuvant of BCG vaccine immunity in vivo (increase in the Th1 type cytokine induction (IFN-γ/IL-12), a novel property that might explored and account for the development of non-toxic therapeutic alternatives.

Material and Methods

Animals

Pathogen-free adult (seven to eight weeks old) BALB/c mice were obtained from Harlan, Co, USA and were housed and maintained in the animal facilities of the campus UACB-UAZ (Zacatecas, Zac. Mexico). All animal experiments were performed according to the protocols approved by bioethical committee of the University Autonome of Zacatecas. Campus XXI and conformed to National Community guidelines (SENASICA AUT-B-C-0514-011).

Immunizations

Groups of seven to eight weeks-old BALB/c female mice were immunized intranasally (i.n.) or by oral route with sterile-phosphate buffered saline (PBS), or with a commercial based Cry1A-Cry2A toxin preparation Bactospeine® DF (Valent Biosciences de Mexico, S.A. de C.V.) (2.5 µg/ml) in a final volume of 10 to 20 µl. One week after first immunization, at intervals of once weeks during a total of three weeks, each group of mice were immunized by i.n. and/or oral route with PBS or commercial product based on Cry1A-Cry2A toxins (Bactospeine). Two weeks after the last immunization, mice were sacrificed, according to the bioethics guidelines of UAZ (SENASICA AUT-B-C-0514-011). Serum and broncho-alveolar lavages were obtained and maintained at -80°C until use.

Enzyme-linked immunoabsorbent assays

To measure specific anti-Cry1A toxins levels in serum and/or broncho-alveolar fluids (BAL), standard indirect ELISA were performed as described previously. Briefly, 96-well plates (Nunc Maxisorb, NY) were coated overnight at 4°C with 1 µg per well of Cry1A toxins dissolved in carbonate buffer (pH 9.6). Non-specific binding was blocked with 3% non-fat milk/0.05% Tween 20 in PBS. After incubating samples overnight a 4°C, plates were extensively washed, and bound antibodies were detected using goat anti-mouse Ig (1:2500); IgA-HRP (1:1000), [IgG1-HRP, IgG2a-HRP, IgG2b-HRP and IgG3-HRP conjugate to a concentration of 1:2500], followed by Streptavidin-Horseradish peroxidases conjugate (Mouse Ig isolotyping ELISA, Bioscience). Color reactions were developed using Tetramethyl-benzidine in 0.05 N citrate-phosphate buffer (pH 5.2), supplemented with 0.01% H2O2. The reaction was stopped with 1M H3PO4. Optical densities were measured at 450 nm using a microplate reader. Amounts of IFN-γ, TNF-α, IL-10, IL-4, or IL-17 in the supernatants were measured by using a specific sandwich ELISA (OptEIA; BD Bioscience BD Pharmingen®) according to the manufacturer’s instructions. Assay sensitivities were 2.5 pg/ml for IFN-γ and 3 for the other cytokines (IL-17, IL-4, IL-10). Data are expressed as the mean ± SEM for each mouse group.

Viability assay

Cell monolayer of pneumocytes class II (A549) was prepared, to 10000 cells per well in a 96 plates and incubated overnight to 37°C, 5% of CO2. Then, the monolayer was washed once with a HBSS solution and culture medium was added. The cells were stimulates as follow: BCG (MOI 10:1), a commercial product based on Cry1A-Cry2A toxins (Bactospeine) (10 µg/ml), BCG+ Cry1A-Cry2A toxins (Bactospeine) (MOI 10:1). As a control of toxicity Ursolic acid (20 µg/ml). Negative control (medium culture). Viability of the cells were determined at 24 and 48 h post stimulation. At each period of time, the supernatant was discarded. Trypan blue (0.01%) was added to the Wells. Alive and death cells were counted at light microscopy. The assays was performed by duplicate.

Statistical analysis

Statistical analysis to determine was calculated using ANOVA. Differences between the means were calculated by Tukey’s test. A P value < 0.05 was considered statistically significant.

Results

Immunogenicity of a commercial based Cry1A-Cry2A toxin preparation (Bactospeine) after intranasal immunization of BALB/c mice.

It has been reported that mice fed with transgenic maize and/or purified Cry1Ab toxin induced humoral and cellular immune responses in serum of mice after sensitization by intraperitoneal or intragastric route. Not induction of IgE or toxicity was observed [29-30]. Herein, a commercial Cry1A based product was evaluated in vitro and in vivo, respectively. To this end, mice were immunized by oral or intranasal route with Bactospeine (Cry1A-Cry2A toxins) (Figure 1). Thus, mice immunized by oral route with Bactospeine (Cry1A-Cry2A toxins) induced humoral response significant with respect to control PBS immunized mice (P < 0.05) but at lower magnitude than after intranasal immunization (P < 0.05) (Figure 1 upper and lower panel). Thus, at systemic level, IgA (0.57 ± 0.042 vs 0.36 ± 0.18) after intranasal immunization was significant. On the other hand, mice immunized by oral route and peritoneal injection with Bactospeine (Cry1A-Cry2A toxins) showed similar responses in IgG and IgA (Figure 1 middle panel). This result was different compared to intranasal immunization with Bactospeine (Cry1A-Cry2A toxins), where an increase in IgA and IgG was observed. Finally, our results showed that both immunization routes induced a similar level of IgM, indicating a non-toxic response.
0.05) and IgM (0.54 ± 0.028 vs 0.35 ± 0.0) (Figure 1) were elicited. While at mucosal level, IgA (0.50 ± 0.016) and IgM (0.54 ± 0.008) were detected in BAL (Figure 1). Not difference in the IgG subclass Abs induced after oral immunization of mice with respect to those immunized by i.n. route either in serum or in BAL (Figure 1, upper and lower panel). However, the magnitude of these antibodies were significant with respect to control PBS immunized mice (P < 0.05) in seric IgG1 (0.63 ± 0.04 vs 0.36 ± 0.005); IgG2a (0.59 ± 0.02 vs 0.36 ± 0.0); IgG2b (0.59 ± 0.014 vs 0.33 ± 0.007) and IgG3 (0.59 ± 0.04 vs 0.35 ± 0.005) (P < 0.05); while IgG subclass such as IgG1 (0.36 ± 0.005); IgG2a(0.36 ± 0.0); IgG2b (0.33 ± 0.007); IgG3 (0.35 ± 0.003) (Figure 1 upper panel) (P < 0.05). Moreover, the magnitude of the antibody response detected in BAL induced by the intranasal immunization of mice with Bactospeine, were significant with respect to control PBS immunized mice of IgM (0.68 ± 0.030) vs (0.36 ± 0.007)) and IgA [(0.61 ± 0.025) vs (0.35 ± 0.007)] (Figure 1 lower panel) (P < 0.05). However, the cells proliferate and restored viability after stimulation of cells (P < 0.05). Around 5-8% of decrease in magnitude was observed in IL-10 (2165 ± 197 vs 444 ± 44 pg/ml); IL-6 (1412 ± 172 vs 444 ± 44 pg/ml); IL-17 (1200 ± 28 vs 117 ± 14 pg/ml); TNF-α (4533 ± 378 vs 362 ± 35 pg/ml); IL-10 (642 ± 103 vs 173 ± 21 pg/ml); and IL-4 (597 ± 59 vs 180 ± 3 pg/ml) (Figure 2-I-II). At mucosal level (detected in BAL); a difference in magnitude was observed in IL-10 (2165 ± 196 vs 647 ± 47 pg/ml); IL-4 (2083 ± 59 vs 58 ± 2 pg/ml); IL-17(2850 ± 815 vs 472 ± 82); (P < 0.05); TNF-α (2176 ± 305 vs 529 ± 17 pg/ml); IL-10 (642 ± 103 vs 173 ± 21 pg/ml); and IL-4 (597 ± 59 vs 180 ± 3 pg/ml) (Figure 2-I-II). Not difference in IL-17 or IL-4 production with respect to control mice [IgM (0.35 ± 0.0) and IgA (0.36 ± 0.0)] was measured at 48 h in comparison with any of the stimulus, Ursolic acid, BCG or BCG + Cry (Figure 3, I-II) (P < 0.05). Around 5-8% of decrease of viability was observed after 24 h post stimulation in comparison with control cells (stimulated with medium only) (P < 0.05). However, the cells proliferate and restored viability was measured at 48 h in comparison with any of the stimulus, Ursolic acid, BCG or BCG + Cry (Figure 3, I-II) (P < 0.05). A commercial product based on Cry1A-Cry2A toxins (Bactospeine) did not affect the viability of pneumocytes class II (A549 human cell line) in vitro.

Next, due to the cholera toxin IL-17-inducing capacity (20-21), we investigate whether the commercial products based on Cry1A-Cry2A toxins (Bactospeine) have this ability. Thus, after intranasal immunization, mice induced at systemic level; mice elicited, IFN-γ (1127 ± 396 vs 149 ± 9 pg/ml); IL-17 (756 ± 96 vs 133 ± 6); TNF-α (5967 ± 651 vs 365 ± 7) and IL-6 (2354 ± 346 vs 392 ± 7 pg/ml) (P < 0.05); IFN-γ (BCG, 14500 ± 823; Cry 17900 ± 283; BCG + Bactospeine (Cry1A+Cry2A) 14575 ± 354) (P < 0.05) (Figure 4 upper panel)(gray bars). Remarkably, an increase in Th1-type cytokines such as IFN-γ (BCG, 14500 ± 823; Cry 17900 ± 283; BCG + Bactospeine (Cry1A+Cry2A) toxins (18890 ± 212) (P < 0.05) and IL-12 (BCG, 102330 ± 1838; Cry 6358 ± 530; BCG + Bactospeine (Cry1A-Cry2A) (15150 ±0.0)(P < 0.05) Figure 4 upper panel(gray bars). Surprisingly, an increase in Th1 type cytokines such as TNF-α (2176 ± 305; 529 ± 17 pg/ml); IL-10 (642 ± 103 vs 173 ± 21 pg/ml); and IL-4 (597 ± 59 vs 180 ± 3 pg/ml) (Figure 2-I-II). Around 5-8% of decrease of viability was observed after 24 h post stimulation in comparison with control cells (stimulated with medium only) (P < 0.05). However, the cells proliferate and restored viability was measured at 48 h in comparison with any of the stimulus, Ursolic acid, BCG or BCG + Cry (Figure 3, I-II) (P < 0.05). A commercial product based on Cry1A-Cry2A toxins (Bactospeine) did not affect the viability of pneumocytes class II (A549 human cell line) acting as an adjuvant after co-administration with M. bovis Bacillus Calmette-Guérin (BCG) vaccine.

Finally, we measured the cytokines induced by the effect of stimulation of A549 epithelial human cell line cells with commercial product based on Cry1A-Cry2A toxins. We found that A549 cells elicited, IL-10 [(BCG, 15140 ± 2382; Cry 18948 ± 1411; BCG+ Bactospeine (Cry1A+Cry2A) 17940 ± 707)] (P < 0.05), and IL-6 [BCG, 11450 ± 0.0; Cry 14825 ± 355; BCG + Bactospeine (Cry1A+Cry2A) toxins] 14575 ± 354 (P < 0.05) (Figure 4 upper panel)(gray bars). Not difference in magnitude was observed in IL-10 (2165 ± 196 vs 647 ± 47 pg/ml); IL-4 (2083 ± 59 vs 58 ± 2 pg/ml); IL-17(2850 ± 815 vs 472 ± 82); (P < 0.05); TNF-α (2176 ± 305 vs 529 ± 17 pg/ml); IL-10 (642 ± 103 vs 173 ± 21 pg/ml); and IL-4 (597 ± 59 vs 180 ± 3 pg/ml) (Figure 4 lower panel, dark gray bars). Not effect in IL-17 or IL-4 cytokine production.
Discussion

*Bacillus thuringiensis* Cry toxins have been shown to be strong immunogens, carrier and adjuvants through different routes of immunization [4-10]. However, still there are safety and bio-ethical concerns regarding its use in agricultural and clinic use [22-28]. Herein, we are reporting that a commercial products based on Cry1A-Cry2A toxins (Bactospeine)(BD Biosciences) did not show any toxicity either *in vivo* or *in vitro* assays; on the contrary, it show a dichotomy effect, as an strong immunogen and as an adjuvant of Th1-type cytokine of *M. bovis* BCG immunity

Despite of a huge amount of evidences supporting the use of the cholera toxin subunit B as a candidate vaccine adjuvant of bystander antigens [17-21], still there are concerns regarding its clinic use. *Bacillus thuringiensis* Cry toxins have been long used for decades for insect biological control [1-3]. In more recent years, it has been shown that pCry1Ac behaves as strong immunogen after different routes of immunization to mice [7-8]. Furthermore, pCry1Ac has been demonstrated that can be used as an adjuvant of clinically important antigens [9-12]. Regarding the mechanism of action of pCry1Ac in mice, it has been proposed that the observed immunogenic properties could involve the interaction of the pCry1Ac with surface proteins localized in the small intestine microvessoly of mice [13], and a more recent study show that pCry1Ac is able to interact with HSP70 followed by signalization through the ERK pathway in macrophages [16]. The effects of pCry1Ac interaction on intestinal epithelium is that can promote the regionalization of some receptors like plgR [5] and increase the expression of FCRn in the intestinal epithelium of adult mice [14].

*Bt* Cry1A toxins, including tCry1Ac is comprised of three domains [1-2], one of them, domain II, is the binding domain; therefore, it is tempting to think that the observed immunogenic and adjuvant properties showed by these toxins might involve domain II of tCry1A [4]. However, not further studies have been made to assess this issue [4], [13-16]. In the present work, with focused to evaluate the non.toxicity of a commercial product Bactospeine (Cry1A-Cry2A toxins) either *in vivo* and *in vitro* assays.

The data obtained, revealed that Bactospeine (Cry1A-Cry2A) did not exert any toxicity (Figure 3I-II) (P < 0.05) on the contrary, through mucosal immunization, either after oral or intranasal route, elicited significant magnitude of Abs isotype (IgM and IgA) as well as IgG subclass Ab; and pro-inflammatory and anti-inflammatory cytokines (Figure 1-II;; 2I-II). (P < 0.05). Remarkably, after oral administration, we found that systemic IFN-γ, TNF-α as well as IL-17 were elicited (Figure 2II) (P < 0.05). Nonetheless, these cytokines were also induced at mucosal level (BAL) even at lesser magnitude (Figure 2I-II). Furthermore, these cytokines were also induced at mucosal level (BAL) even at lesser magnitude (Figure 2I-II). Furthermore, potential Bactospeine immunogenic properties were strengthened because after *in vitro* co-stimulation of pneumoytes class II (A549 human cell line)(Figure 4I-II), exerted an adjuvant activity of the BCG vaccine Th1-type inducing immunity (IFN-g, IL-12) Figure 4-II, p< 0.05), an ability that is being currently addressed. In summary, the data reported in this work, highlight a novel property of commercial product based on Cry1A-Cry2A toxins (Bactospeine) as immunogen and more important as an adjuvant, which open a potential alternative to be taken in account for the development of non-toxic subunits agents in infectious disease and other chronic human diseases.

Figure 1. A commercial product based on Cry1A-Cry2A toxins (Bactospeine) acts like a strong immunogen (IgM/IgA, and IgG subclass) through intranasal (I) and after oral immunization of BALB/c mice (II). After sacrifice of mice serum and BAL washes were recovered and antibodies (mouse isotyping BD Biosciences) were detected either in serum or BAL using ELISA. Differences are significant at P<0.05 with respect to control PBS immunized mice (*) and between the i.n/oral routes (**).
Figure 2. A pattern of Th1, Th2 and Th3 cytokines are elicited after intranasal (I) and oral immunization (II) of mice with a commercial product Cry1A-Cry2A toxins (Bactospeine). After the third of immunization, mice were sacrificed and serum and BAL washes were recovered. Cytokine production were measured by ELISA. Values are expressed in pg/ml and represent media ± SEM of samples tested in duplicates from each group of mice. Differences are significant at P<0.05 with respect to control PBS immunized mice (*) for Abs and cytokines and between the i.n/oral routes (**) (for Abs only).

Figure 3. A commercial product based on Cry1A-Cry2A toxins (Bactospeine) is not toxic to pneumocytes class II (A549 human cell lines). To assess the toxicity of the mentioned formulation, a monolayer of A549 cells were stimulated as follow: BCG (MOI 10:1), Cry protein (10 µg/ml), BCG+ Cry (MOI 10:1). As a control of toxicity, ursolic acid (20 µg/ml) was used. Negative control (medium culture). Viability of the cells were determined at 24 and 48 h respectively, after stimulation. Thereafter each time, the supernatant was discarded. Trypan blue (0.01%) was added to the wells and alive and death cells were counted at light microscopy. The assays was performed by duplicate. Differences are significant at P<0.05 with respect to control PBS immunized mice (*) and with respect to ursolic acid (**).
Figure 4. A commercial product based on Cry1A-Cry2A toxins (Bactospeine) boosted the BCG vaccine Th1 type cytokine production in vitro. Pneumocytes class II (A549 cells) were co-stimulated as described in mat and methods. Cytokine production (IL10, IL-6, IFNγ, IL-12, IL17) (BD Biosciences PharmingenTM were measured in the supernatant of the cell culture of each treatment and measured by ELISA. Values are expressed in pg/ml and represent media ± SEM of samples tested in duplicates from each group of mice. Differences are significant at P<0.05 with respect to control PBS immunized mice (*) and with respect to BCG vaccination without boost (**).

Disclosure of statement: The authors declare no conflict of interest.

Acknowledgements: The present work was supported by SEP (Programs; PRODEP, PIFI, PERFIL-PRODEP), and SNI CONACYT. The authors are grateful for the technical assistance of the members of the immunobiology lab group from ENCB.IPN, Mexico, City.

References


